Cardiac Assessment by PV Loop in IPAH and Scleroderma PAH

Launched by JOHNS HOPKINS UNIVERSITY · Oct 26, 2020

Keywords

ClinConnect Summary

This clinical trial is looking to understand why some people with scleroderma develop pulmonary arterial hypertension (PAH), which is high blood pressure in the lungs, and heart failure. It's also investigating why individuals with idiopathic PAH, meaning the cause is unknown, may experience a weakened heart muscle. The researchers will assess how the right side of the heart responds to standard treatments for PAH in both groups of patients. If you have scleroderma-associated PAH or idiopathic PAH and need a specific heart test called a right heart catheterization, you might be eligible to participate in this study.

To be eligible, you need to be 18 years or older and have a diagnosed case of scleroderma or idiopathic PAH. However, if you have high blood pressure caused by heart failure or are unable to provide consent for yourself, you may not qualify. If you join the study, blood and tissue samples will be taken during your usual care procedures, but this will not involve extra steps beyond what you would normally have done. The trial is currently recruiting participants, and it aims to provide valuable insights into how these conditions affect heart health.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients 18 years or older with clinically diagnosed scleroderma or presumed/known idiopathic pulmonary hypertension.
• Exclusion Criteria:
• • Patients found to have secondary pulmonary hypertension (PH due to left heart failure) on clinical RHC.
• • Hemodynamically unstable patients (systolic blood pressure \< 90mmHg, vasopressor requirement).
• • Patients whom are unable to give consent for themselves.
• • Patients with RV clot or septal aneurysm will be excluded.
• • In order to undergo the clinical right heart catheterization procedures, pregnancy testing (urine or serum) is standard of care.
• • Pregnancy